Extrait

To assess the clinical benefit rate with rucaparib in previously treated patients with metastatic breast cancer with BRCAness profile (defined by Clovis genomic signature), and if it is significant, to assess the overall response rate.

Critère d'inclusion

• Patients with progressing metastatic breast cancer pretreated with at least one line of chemotherapy at the metastatic setting

Liens

• ictrp
• euctr